Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma Article

Iwamoto, Fabio M, Lamborn, Kathleen R, Robins, H Ian et al. (2010). Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma . NEURO-ONCOLOGY, 12(8), 855-861. 10.1093/neuonc/noq025

Open Access

cited authors

  • Iwamoto, Fabio M; Lamborn, Kathleen R; Robins, H Ian; Mehta, Minesh P; Chang, Susan M; Butowski, Nicholas A; DeAngelis, Lisa M; Abrey, Lauren E; Zhang, Wei-Ting; Prados, Michael D; Fine, Howard A

sustainable development goals

authors

publication date

  • August 1, 2010

webpage

published in

keywords

  • ANGIOGENESIS
  • Clinical Neurology
  • ENDOTHELIAL GROWTH-FACTOR
  • EUROPEAN ORGANIZATION
  • EXPRESSION
  • Gliadel wafers
  • IL13-PE38QQR
  • Life Sciences & Biomedicine
  • MALIGNANT GLIOMAS
  • MESSENGER-RNA
  • Neurosciences & Neurology
  • Oncology
  • PROGRESSION
  • PROLONGS SURVIVAL
  • Science & Technology
  • TUMOR VASCULATURE
  • TYROSINE KINASE INHIBITOR
  • cintredekin besudotox
  • convection-enhanced delivery
  • glioblastoma multiforme

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 855

end page

  • 861

volume

  • 12

issue

  • 8